Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

Size: px
Start display at page:

Download "Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms"

Transcription

1

2

3 Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs

4 Bayer s High Tech Research platform integrates leading technology experts Technology platform to be completed: Genomics support for metabolic disorders, Toxicogenomics and Pharmacogenomics Gene target Assay Lead structure Candidate Development product Millennium Novalon Oxford Asymmetry Lion CyBio ComGenex OGS Morphosys ArQule Incyte Affymetrix Gene targets for Metabolic Disorders Pharmacogenomics Toxicogenomics

5 Obesity and Diabetes Alliance

6 Bayer completes its access to gene targets for all research areas with this Metabolic Disorders Alliance Gene based disease mechanisms (Genomics) are the basis of modern pharmaceutical research Bayer s collaboration with Curagen completes Bayer s access to gene based targets for all research areas Curagen is a leading technology company with broad expertise in the field of genomics, especially in metabolics disorders and owns a broad portfolio of proprietary gene targets for diabetes and obesity treatment

7 New structure for collaboration between pharmaceutical and biotech industry Broad risk and reward sharing from research to commercialization phase of new therapeutic products Development costs up to $ 750 M will be shared equally between both partners Profit sharing after successful market introduction instead of milestone and royalty payments Profits will be shared on the basis of cost contribution during research and development

8 Details of the Bayer - Curagen Collaboration in Diabetes and Obesity Basis of collaboration: Delivery of 80 drug targets for diabetes and obesity by Curagen Processing of the targets at Bayer development candidates Research Development Commercialization Bayer! Assays (HTS)! Development candidates! Responsibility for Development till Commercialization! Responsibility for Manufacturing and worldwide Commercialization Curagen! Supply of 80 Gene targets! Toxicogenomics Screening of development candidates! Technology transfer (functional genomics)! Participates with 50 % in development expenditures! Option: Copromotion rights in the US Profits will be shared according to participation in R&D costs 56 % for Bayer and 44 % for Curagen

9 Toxicogenomics / Pharmacogenomics Collaboration

10 Drug Discovery Research is Technology Driven Goal Ziel Strategy Implementation Disease? Drug Pathomechanism Molecular target Screening Optimization Development Genomics Functional Genomics Bioinformatics High Throughput screening Combinatorical Chemistry Toxicogenomics Pharmacogenomics

11 Integration of Toxico- and Pharmacogenomics in the Research and Development process will improve the decision basis for drug candidate selection Disease gene (Gene defect) Genome analysis Genomics Assay Screen Substance Test of compound specific Expression of Tox -Genes Optimization Development candidate Clinical Development Identification of genes and gene products which are modified by gene defects (Surrogate markers, SNP-patterns) Patient stratification Toxicogenomics Pharmacogenomics

12 Scope and background of Toxicogenomics Collaboration Goal: Basis: Early prediction of tolerability and improvement of drug development candidate selection Analysis of toxic potential of substances (Hits, Leads) by use of gene expression profiles Strategy:! Development of generic reference database of known toxic substances! Development of high throughput Tox gene chip assay Routine use:! Testing of substances during hit and lead phase! Establishment of Bayer proprietary substance database

13 Toxicogenomics and Pharmacogenomics will improve the probability for success for drug development projects.! Pharmacogenomics und Toxicogenomics are the next logical steps after Functional Genomics; they complement and expand Bayer s High Tech Research Platform and will improve the quality of the development candidates.! Improve selection process and prioritization of preclinical candidates through prediction of potential side effects by toxicogenomic analyses.! Pharmacogenomic technologies will enable Bayer to preselect responders and monitor drug reaction early during therapy.! Toxicogenomics and pharmacogenomics will help Bayer to reduce drug development costs and time to market and create safer and more efficacious drugs.! Bayer will have access to all diagnostic assays found during the Toxicogenomics and Pharmacogenomics collaboration.! This collaboration with a leading technology expert in this field will ensure fast applicability and competitiveness of the new technologies.

14 Scope and background of Pharmacogenomics Collaboration Goal: Improve response prediction for substances (Surrogate-Parameter) and patient selection (stratification) by genotyping Basis:! Different expression profiles in diseased and healthy people are used for identification of potential therapy responders! SNP s will be used for individual drug specific response Routineuse:! Detailed gene expression profiling of development candidates Response prediction! SNP-Analysis of drug targets Basis for NAD diagnostics! Pathway-Analysis of targets Identification of Surrogate-Parameters

15 Implications of Pharmacogenomics on drug development and therapy Research Development Therapy Genetarget Substances Prediction of toxicity, metabolism and response Genotyping of patients Minimization of side effects Maximization of response Diagnostics New definition of disease pattern Individualized Therapy

16 CuraGen Engineering Cures Through Genes GENOMICS

17 CuraGen Safe Harbor Statement This presentation contains forward-looking statements about CuraGen and some of our potential therapeutic products, including statements regarding the development of antibodies, proteins, and and small molecules as potential therapeutics; our ability to successfully enhance and develop our r technologies; and both CuraGen s and Bayer s respective abilities to adhere to the terms of their alliance. While we make our best efforts to be accurate in making forward- looking statements, any such statements are subject to risks and uncertainties that could cause actual results to vary materially. These risks include the possibility of delays in the testing of potential therapeutic products; the risk that preclinical trials may not result in successful clinical trials or marketable products; the risk that we will be unable to successfully finance, secure regulatory approval of, and market any of our therapeutic product t candidates; and our reliance on research collaborations for the development and testing of some of our potential therapeutic products. ( )

18 Opportunity: Turning the Genome Into Drugs Intersection of Information Technology and Molecular Biology

19 CuraGen s Opportunity " Pharmaceuticals Germ Theory Organic Chemistry " Biopharmaceuticals Replacement Therapy Recombinant DNA " Genomic Based Drugs Inherited (Nature) VS. Environmental (Nurture) Functional Genomics & Information Technology Process Driven, Systematic and Comprehensive

20 CuraGen s Business Strategy " Leading Genomic Technologies & Internet Portal " Near Term Revenues and Knowledge from Collaborations " Long Term Sustainability from Proprietary Product Pipeline

21 Functional Genomic Technologies & Expertise SeqCalling Sequencing GeneCalling Transcript Profiling PathCalling Pathways SNPCalling Genotyping

22 Genome-Scale Discovery Process Toxicogenomic and pharmacogenomic databases Treatment models Drugs Disease Mining Targets Animal models CuraGen s Annotated Genome Surgical models Pathway databases Cellular models Human Genetics SNPs in clinical populations SNPs in targets Detailed patient records

23 Pharmaceutically Relevant Genes Drug Target Classes CuraGen s Annotated Genome Non-CRGN Patented Genes Evaluating at CuraGen Protein Therapeutics (54 Marketed) 357 Antibody Targets (9 Marketed) 1557 Small Molecule Targets (383 Marketed) 3290 Over 22 Billion Nucleotides Analyzed To Create Our Annotated Genome

24 Pharmacogenomic and Toxicogenomic Collaboration " Bayer to purchase $85 million in CRGN stock " Bayer to pay CRGN $39 million for Pharmacogenomic and Toxicogenomic services " Toxicogenomic database to be developed and commercialized by CRGN, with royalties paid to Bayer " CRGN to conduct preclinical and clinical analysis on Bayer s candidates across all disease areas " Technology transfer to be negotiated during later stages of contract

25 Obesity and Diabetes Discovery, Development, and Commercialization on Alliance " Bayer and CRGN have committed approximately $600 million during the preclinical stages of development through in-kind contributions " CRGN to provide 80 targets over 5 years " Bayer to conduct HTS, combinatorial chemistry, medicinal chemistry, and early preclinical work " Companies have committed to sharing later stage preclinical and clinical development expenses up to $750 million " Companies to jointly commercialize and share profits from resulting pharmaceutical products

26 Making Our Mark " Leading Platform of Functional Genomic Technologies " Premier Partners Establish CuraGen as a Genomics Leader " Ownership of Disease Programs & Significant Internal Product Pipeline A Drug Discovery Engine for Identifying Novel Products with Tremendous Potential